View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 31, 2022

Accutar doses first patient in Phase I prostate cancer treatment trial

The trial will analyse the safety, tolerability, pharmacokinetics and initial anti-tumour activity of AC0176 for mCRPC.

Accutar Biotechnology has dosed the first subject in the Phase I clinical trial of its investigational therapy, AC0176, to potentially treat metastatic castration-resistant prostate cancer (mCRPC) patients.

An orally bioavailable, chimeric degrader molecule, AC0176 is created to act on the androgen receptor (AR) with increased selectivity and potency.

The activation of AR, a hormone-regulated transcription factor, plays a crucial role in the development and progression of prostate cancer. 

The open-label, multicentre trial will analyse the safety, tolerability, pharmacokinetics and initial anti-tumour activity of AC0176 in individuals with mCRPC. 

It will enrol subjects who have advanced after receiving a minimum of two systemic therapies.

Establishing the recommended dose of AC176 that can be administered to trial subjects is one of the keys goals of the trial. 

AC0176 was found to offer robust AR protein degradation with a wide coverage of AR mutants in preclinical studies. 

It also was found to have favourable pharmacological properties and anti-tumour activity in animal models.

In December last year, the company obtained clearance for its investigational new drug application (IND) from the US Food and Drug Administration (FDA) to commence the trial of AC0176 for mCRPC. 

Accutar Biotechnology CEO Jie Fan said: “The initiation of this study marks the second programme from our AI-enabled drug discovery platform and our chimeric degrader portfolio to enter the clinic. 

“AC0176 was designed to potently degrade both AR wildtype and prevalent AR mutants which confer drug resistance to current AR-targeted therapies, including but not limited to L702H, T878A, H875Y, W742C. 

“We are excited about the differentiated therapeutic profile of AC0176 and its broad potential to treat prostate cancer patients.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU